MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT^® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:

Jason Adair

Chief Business Officer

919.328.4350

jason.adair@liquidia.com

Media:

Patrick Wallace

Director, Corporate Communications

919.328.4383

patrick.wallace@liquidia.com

Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025